ゲミグリプチン 化学特性,用途語,生産方法
効能
糖尿病治療薬, DPP-4阻害薬
説明
Gemigliptin is a prolyl-specific dipeptidyl aminopeptidase IV
(DPP IV, DPP-4, CD26) inhibitor approved for the treatment of type
2 diabetes mellitus by the Korean Food and Drug Administration in
2012. Gemigliptin was discovered and developed by LG Life
Sciences and is now the sixth DPP-4 inhibitor approved for the
treatment of type 2 diabetes. At the time this review was prepared,
there were no publications describing the discovery strategy
and preclinical data that led to the advancement of gemigliptin to the clinic.
使用
Gemigliptin Hydrochloride is used in biological studies as a novel dipeptidyl peptidase IV (DPP-IV) inhibitors and potential antidiabetic drug.
ゲミグリプチン 上流と下流の製品情報
原材料
準備製品